IDEXX Laboratories, Inc. $IDXX Shares Bought by Congress Asset Management Co.

Congress Asset Management Co. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9,894.0% in the 4th quarter, Holdings Channel reports. The firm owned 153,908 shares of the company’s stock after buying an additional 152,368 shares during the period. Congress Asset Management Co.’s holdings in IDEXX Laboratories were worth $104,123,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in IDXX. Vanguard Group Inc. grew its position in IDEXX Laboratories by 0.9% in the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after buying an additional 86,040 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after acquiring an additional 605,290 shares during the last quarter. Invesco Ltd. boosted its stake in shares of IDEXX Laboratories by 14.0% during the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after acquiring an additional 161,782 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of IDEXX Laboratories by 16.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after acquiring an additional 187,967 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after acquiring an additional 326,348 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $578.51 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The stock’s 50-day moving average is $642.81 and its two-hundred day moving average is $664.28. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The firm has a market cap of $46.00 billion, a P/E ratio of 44.26, a PEG ratio of 3.50 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IDXX. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.